Botanix Pharmaceuticals Limited (BXPHF)
USD 0.25
(13.64%)
USD 0.25
(13.64%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 | 601.82 Thousand AUD | -93.83% |
| 2023 | 9.74 Million AUD | -38.84% |
| 2022 | 15.94 Million AUD | 55.26% |
| 2021 | 10.26 Million AUD | -57.68% |
| 2020 | 24.25 Million AUD | 13.05% |
| 2019 | 21.45 Million AUD | 65.83% |
| 2018 | 12.94 Million AUD | 169.25% |
| 2017 | 4.8 Million AUD | 197.51% |
| 2016 | 1.61 Million AUD | 190.87% |
| 2015 | 555.37 Thousand AUD | -75.53% |
| 2014 | 2.27 Million AUD | 36.44% |
| 2013 | 1.66 Million AUD | 11.62% |
| 2012 | 1.49 Million AUD | -1.93% |
| 2011 | 1.51 Million AUD | -23.59% |
| 2010 | 1.98 Million AUD | -37.01% |
| 2009 | 3.15 Million AUD | -0.45% |
| 2008 | 3.17 Million AUD | -14.65% |
| 2007 | 3.71 Million AUD | 16.76% |
| 2006 | 3.18 Million AUD | -1.77% |
| 2005 | 3.24 Million AUD | 75.0% |
| 2004 | 1.85 Million AUD | -23.63% |
| 2003 | 2.42 Million AUD | 143.96% |
| 2002 | 994 Thousand AUD | 124.89% |
| 2001 | 441.99 Thousand AUD | 112.95% |
| 2000 | -3.41 Million AUD | 56.72% |
| 1999 | -7.88 Million AUD | 51.95% |
| 1998 | -16.41 Million AUD | -231.99% |
| 1997 | 12.43 Million AUD | -1.57% |
| 1996 | 12.63 Million AUD | 66.67% |
| 1995 | 7.58 Million AUD | 18.53% |
| 1994 | 6.39 Million AUD | 24.87% |
| 1993 | 5.12 Million AUD | 32.11% |
| 1992 | 3.87 Million AUD | 27.28% |
| 1991 | 3.04 Million AUD | 4.71% |
| 1990 | 2.9 Million AUD | 2.47% |
| 1989 | 2.83 Million AUD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q3 | 3.92 Million AUD | 56.89% |
| 2024 Q1 | 2.45 Million AUD | 5.26% |
| 2024 FY | 9.34 Million AUD | -4.19% |
| 2024 Q2 | 2.5 Million AUD | 2.06% |
| 2024 Q4 | 3.92 Million AUD | 0.0% |
| 2023 FY | 9.74 Million AUD | -38.84% |
| 2023 Q2 | 7.42 Million AUD | 369.47% |
| 2023 Q3 | 2.01 Million AUD | -72.91% |
| 2023 Q1 | 1.58 Million AUD | -83.08% |
| 2023 Q4 | 2.32 Million AUD | 15.8% |
| 2022 Q1 | 1.16 Million AUD | -70.49% |
| 2022 Q3 | 1.65 Million AUD | -74.44% |
| 2022 Q4 | 9.34 Million AUD | 466.11% |
| 2022 Q2 | 6.45 Million AUD | 453.51% |
| 2022 FY | 15.94 Million AUD | 55.26% |
| 2021 Q4 | 3.95 Million AUD | 346.05% |
| 2021 FY | 10.26 Million AUD | -57.68% |
| 2021 Q1 | 962.6 Thousand AUD | -90.04% |
| 2021 Q2 | 6.22 Million AUD | 546.17% |
| 2021 Q3 | 886.21 Thousand AUD | -85.75% |
| 2020 Q1 | 3.13 Million AUD | -75.76% |
| 2020 Q3 | 2.23 Million AUD | -84.6% |
| 2020 Q2 | 14.48 Million AUD | 362.65% |
| 2020 FY | 24.25 Million AUD | 13.05% |
| 2020 Q4 | 9.66 Million AUD | 333.37% |
| 2019 FY | 21.45 Million AUD | 65.83% |
| 2019 Q1 | 634.97 Thousand AUD | 31.33% |
| 2019 Q2 | 634.97 Thousand AUD | 0.0% |
| 2019 Q3 | 1.96 Million AUD | 210.18% |
| 2019 Q4 | 12.92 Million AUD | 556.05% |
| 2018 Q4 | 483.47 Thousand AUD | 0.0% |
| 2018 Q3 | 483.47 Thousand AUD | 11.53% |
| 2018 Q2 | 433.5 Thousand AUD | -0.0% |
| 2018 FY | 12.94 Million AUD | 169.25% |
| 2018 Q1 | 433.5 Thousand AUD | 28.18% |
| 2017 Q2 | 244.73 Thousand AUD | -0.0% |
| 2017 FY | 4.8 Million AUD | 197.51% |
| 2017 Q4 | 338.19 Thousand AUD | 0.0% |
| 2017 Q1 | 244.73 Thousand AUD | 0.0% |
| 2017 Q3 | 338.19 Thousand AUD | 38.19% |
| 2016 FY | 1.61 Million AUD | 190.87% |
| 2015 FY | 555.37 Thousand AUD | -75.53% |
| 2014 FY | 2.27 Million AUD | 36.44% |
| 2013 FY | 1.66 Million AUD | 11.62% |
| 2012 FY | 1.49 Million AUD | -1.93% |
| 2011 FY | 1.51 Million AUD | -23.59% |
| 2010 FY | 1.98 Million AUD | -37.01% |
| 2009 FY | 3.15 Million AUD | -0.45% |
| 2008 FY | 3.17 Million AUD | -14.65% |
| 2007 FY | 3.71 Million AUD | 16.76% |
| 2006 FY | 3.18 Million AUD | -1.77% |
| 2005 FY | 3.24 Million AUD | 75.0% |
| 2004 FY | 1.85 Million AUD | -23.63% |
| 2003 FY | 2.42 Million AUD | 143.96% |
| 2002 FY | 994 Thousand AUD | 124.89% |
| 2001 FY | 441.99 Thousand AUD | 112.95% |
| 2000 FY | -3.41 Million AUD | 56.72% |
| 1999 FY | -7.88 Million AUD | 51.95% |
| 1998 FY | -16.41 Million AUD | -231.99% |
| 1997 FY | 12.43 Million AUD | -1.57% |
| 1996 FY | 12.63 Million AUD | 66.67% |
| 1995 FY | 7.58 Million AUD | 18.53% |
| 1994 FY | 6.39 Million AUD | 24.87% |
| 1993 FY | 5.12 Million AUD | 32.11% |
| 1992 FY | 3.87 Million AUD | 27.28% |
| 1991 FY | 3.04 Million AUD | 4.71% |
| 1990 FY | 2.9 Million AUD | 2.47% |
| 1989 FY | 2.83 Million AUD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Capstone Therapeutics Corp. | 10.86 Million USD | 94.462% |
| Skye Bioscience, Inc. | 13.54 Million USD | 95.558% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 98.385% |
| Nascent Biotech, Inc. | 2.22 Million USD | 73.011% |
| Qrons Inc. | 643.67 Thousand USD | 6.503% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -44.85% |
| Adynxx, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | 5.04 Million USD | 88.064% |
| BioStem Technologies, Inc. | 22.97 Million USD | 97.381% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | 34.833% |
| CSL Limited | 3.44 Billion USD | 99.983% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 98.952% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 97.964% |
| Rebus Holdings, Inc. | 664 Thousand USD | 9.364% |
| Burzynski Research Institute, Inc. | 1.33 Million USD | 54.934% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -54.485% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 96.241% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 99.307% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 87.763% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -129.943% |
| SQZ Biotechnologies Company | 85.61 Million USD | 99.297% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | 79.363% |
| Propanc Biopharma, Inc. | 1.5 Million USD | 59.929% |
| Mesoblast Limited | 5.9 Million USD | 89.803% |
| Marizyme, Inc. | 19.23 Million USD | 96.872% |
| Genus plc | 147.7 Million USD | 99.593% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 93.145% |
| Pharming Group N.V. | 225.49 Million USD | 99.733% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | 70.624% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | 55.14% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 92.783% |
| ContraFect Corporation | 56.88 Million USD | 98.942% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | 86.349% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | 59.302% |
| IMV Inc. | 37.7 Million USD | 98.404% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | 78.432% |
| MultiCell Technologies, Inc. | 567.42 USD | -105962.529% |
| ONE Bio Corp. | 6.44 Million USD | 90.661% |
| Accustem Sciences Inc. | 3.74 Million USD | 83.936% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 99.3% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -13.132% |
| Q BioMed Inc. | 3.43 Million USD | 82.488% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 97.565% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | 77.096% |
| Biomind Labs Inc. | 994.18 Thousand USD | 39.466% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 99.394% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | 65.799% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 91.042% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | 67.72% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 2507.28% |
| Curative Biotechnology, Inc. | 1.83 Million USD | 67.205% |
| GB Sciences, Inc. | 1.42 Million USD | 57.633% |
| Alpha Cognition Inc. | 9.7 Million USD | 93.799% |
| HST Global, Inc. | 140.9 Thousand USD | -327.104% |
| Wesana Health Holdings Inc. | 1.12 Million USD | 46.501% |
| Halberd Corporation | 74.84 Thousand USD | -704.121% |
| Enzolytics Inc. | 2.17 Million USD | 72.387% |
| Agentix Corp. | 1.37 Million USD | 56.128% |
| Resverlogix Corp. | 12.71 Million USD | 95.266% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | 83.515% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 99.961% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | 42.354% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | 74.976% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | 61.895% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | 82.325% |
| AVAX Technologies, Inc. | 7.31 Million USD | 91.767% |
| Zenith Capital Corp. | 8.94 Million USD | 93.27% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.927% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -3354.566% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | 75.489% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -250.897% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | 68.67% |
| Kadimastem Ltd | 2.41 Million USD | 75.029% |
| Helix BioMedix, Inc. | 1.97 Million USD | 69.482% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -231.609% |
| LadRx Corporation | 3.81 Million USD | 84.212% |
| Cell Source, Inc. | 4.32 Million USD | 86.086% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | 34.833% |
| NovAccess Global Inc. | 2.46 Million USD | 75.603% |
| Affymax, Inc. | 39.38 Million USD | 98.472% |
| Itoco Inc. | 919.14 Thousand USD | 34.524% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | 85.801% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | 46.218% |
| Mobile Lads Corp. | 554.54 Thousand USD | -8.525% |
| CytoDyn Inc. | 18.05 Million USD | 96.667% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -2291.116% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -173.458% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | 57.612% |
| SYBLEU INC | 160.87 Thousand USD | -274.089% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | 66.866% |
| International Stem Cell Corporation | 5.27 Million USD | 88.582% |
| Bioxytran, Inc. | 3.82 Million USD | 84.246% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -1043.232% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -2858.364% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 98.341% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | 62.805% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | 18.213% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | 80.655% |
| Neutra Corp. | 243.82 Thousand USD | -146.829% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 96.553% |
| PureTech Health plc | 144.59 Million USD | 99.584% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 97.063% |
| IXICO plc | 4.7 Million USD | 87.214% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 93.159% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 99.489% |
| CSL Limited | 3.89 Billion USD | 99.985% |
| Cellectis S.A. | 97.32 Million USD | 99.382% |